SEC Form 6-K filed by Cardiol Therapeutics Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-40712
Cardiol Therapeutics Inc.
(Name of registrant)
602-2265 Upper Middle Road East
Oakville, Ontario L6H 0G5
Canada
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| x Form 20-F | ¨ Form 40-F |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CARDIOL THERAPEUTICS INC. | ||
| (Registrant) | ||
| Date: October 10, 2024 | By: | /s/ Chris Waddick |
| Name: Chris Waddick | ||
| Title: Chief Financial Officer |
Form 6-K Exhibit Index
| Exhibit Number |
Document Description | |
| 99.1 | News Release dated October 10, 2024 – Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares |